Gemini enters business combination deal with Disc Medicine
The proceeds will be utilised to advance the pipeline of Disc to clinical trials and provide runway into 2025.

The proceeds will be utilised to advance the pipeline of Disc to clinical trials and provide runway into 2025.
GBT takeover complements and boosts Pfizer’s expertise in rare haematology.
Eltanexor is currently being analysed in an open-label Phase I/II trial in relapsed/refractory MDS patients.
Out of total payment of up to $435m, ADC Therapeutics will get an upfront payment of $55m from Sobi.
Following the acquisition, AstraZeneca plans to advance the development of TNB-486 for B-cell hematologic malignancies.
The CMA is supported by the open-label, multi-centre Phase Ib/II CARTITUDE-1 clinical trial of cilta-cel to treat RRMM.
The latest approval is based on findings from a Phase III AGILE clinical trial of Tibsovo plus azacytidine in AML…
The company intends to commence a Phase I/II trial of EDIT-301 in transfusion-dependent beta thalassemia patients this year.
Thank you for subscribing to Pharmaceutical Technology